A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

Type of Cancer
Skin and Soft Tissue
Locations
Hackensack
Sponsor
Alliance
Protocol Number
A091202
Cancer Diagnosis
To Learn More Call
201-510-0910